US · Healthcare · Drug Manufacturers - General
EPS came in at 3.60 against a street estimate of 3.04 — a beat of 18.4%.
Analysts rate Biogen Inc a buy (17 buy, 20 hold, 0 sell out of 37) with an average price target of $234.35.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.81% |
| PRIMECAP Management Company | 9.99% |
| FMR Inc | 8.67% |
| Vanguard Capital Management, LLC | 6.45% |
| State Street Corp | 4.85% |
| Vanguard Portfolio Management, LLC | 4.42% |
| Geode Capital Management, LLC | 2.94% |
| Wellington Management Company LLP | 2.00% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-29 |
| Results announced · Q3 2026 | 2026-07-29 |
| Results announced · Q3 2026 | 2026-07-01 |
| Shareholder vote results · Q2 2026 | 2026-06-10 |
| Material agreement · Q2 2026 | 2026-05-14 |
| Quarterly report · Q1 2026 | 2026-04-29 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Annual report FY2025 | 2026-02-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquired in-process R&D and milestone expenses from strategic acquisition Biogen announced one-time charges for research and development acquisitions and milestone payments. In Q2 2026, the company expects a $164 million pre-tax charge that will reduce earnings pe | 2026-07-01 |
| Consummation of merger with Apellis Pharmaceuticals completed Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026. This 8-K filing is primarily a procedural announcement confirming the merger closure and documenting required fin | 2026-05-14 |
| Collaboration and license agreements with upfront and milestone payments Biogen announced that its Q1 2026 financial results will include a one-time charge of approximately $34 million ($0.19 per share impact) related to acquired in-process research and developme | 2026-04-06 |
| Entered into Agreement and Plan of Merger with Apellis Pharmaceuticals Biogen Inc. announced on March 31, 2026, that it has agreed to acquire Apellis Pharmaceuticals, Inc. in an all-cash tender offer transaction. Under the merger agreement, Biogen will pay $41. | 2026-03-31 |
| Acquired in-process R&D and upfront milestone expenses of approximately $222 million Biogen announced that its Q4 2025 financial results will include a one-time charge of approximately $222 million ($1.26 per share) related to acquired in-process research and development (IP | 2026-01-14 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Biogen Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.